Literature DB >> 3208796

Comparison of the pharmacokinetics of porcine calcitonin in saline and in gelatin diluents in healthy volunteers.

S G Brooks1, K R Butterworth, R B Christie, J Fox.   

Abstract

A randomised 2-way crossover study was carried out in nine healthy male volunteers to compare the pharmacokinetics of porcine calcitonin (pCT) following i.m. administration of 160 i.u. of pCT in physiological saline or in a solution of hydrolysed gelatin. A new radioimmunoassay for pCT is described. It employs an antiserum raised in a guinea pig and a labelled tracer prepared from highly purified pCT. While comparable mean areas under the serum concentration-time curve for both dosage forms indicate equivalent bioavailability, the serum pCT profiles were different; peak pCT levels of 8.3 +/- 0.8 ng ml-1 (s.e.m.) occurred at 13 +/- 2 min (s.e.m.) with peak levels of 4.8 +/- 0.5 ng ml-1 (s.e.m.) when the gelatin diluent was used. The hypocalcaemic effects produced by the two preparations of pCT were of short duration (less than 1 h) and of a similar magnitude (-0.08 to -0.12 mmol.l-1). Comparable degrees of hypophosphataemia (-0.11 to -0.15 mmol.l-1) were observed 20 min post-injection. The administration of pCT in gelatin and saline diluents resulted in markedly different pharmacokinetic profiles. Whether there are therapeutic advantages in the use of either diluent remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208796     DOI: 10.1007/BF03191309

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  13 in total

1.  Thyrocalcitonin: parameters of bio-assay.

Authors:  R J Schlueter; A L Caldwell
Journal:  Endocrinology       Date:  1967-10       Impact factor: 4.736

2.  Escape from inhibition or resorption in cultures of fetal bone treated with calcitoninand parathyroid hromone.

Authors:  J A Wener; S J Gorton; L G Raisz
Journal:  Endocrinology       Date:  1972-03       Impact factor: 4.736

3.  Effects of calcitonin therapy in deafness associated with Paget's disease of bone.

Authors:  W H Moffatt; J D Morrow; N Simpson
Journal:  Br Med J       Date:  1974-10-26

4.  Treatment of hypercalcaemia with calcitonin.

Authors:  T E West; L Sinclair; M Joffe; J L O'Riordan
Journal:  Lancet       Date:  1971-04-03       Impact factor: 79.321

5.  High-dosage short-term corticotrophin therapy in acute asthma.

Authors:  I W Glick; M Friedman
Journal:  Thorax       Date:  1969-07       Impact factor: 9.139

6.  Use of confidence intervals in analysis of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

7.  Plasma kinetics and acute effects of pharmacologic doses of porcine calcitonin in man.

Authors:  B L Riggs; C D Arnaud; R S Goldsmith; W F Taylor; J T McCall; A D Sessler
Journal:  J Clin Endocrinol Metab       Date:  1971-07       Impact factor: 5.958

Review 8.  Thyrocalcitonin.

Authors:  P F Hirsch; P L Munson
Journal:  Physiol Rev       Date:  1969-07       Impact factor: 37.312

9.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

10.  Radioimmunoassay for calcitonin.

Authors:  H Heath; G W Sizemore
Journal:  Clin Chem       Date:  1982-05       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.